Tizanidine
Product Images NDC 60760-719

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 60760-719). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tiz (Tizanidine 60760 719 04)

Packaging label for Tizanidine Tablets, USP 2mg by St. Mary's Medical Park Pharmacy. Label includes product name, strength (2mg), quantity (4 tablets), and storage instructions for controlled room temperature (15°-30°C). Manufacturer listed as ALKALOIDA Chemical Company Zrt., Hungary. Contains barcode and regulatory identifiers with some placeholders for lot number and expiration date.*

FDA Label Image

Tizanidine-1 (Tizanidine 1)

Chemical structure of Tizanidine hydrochloride, showing the arrangement of chlorine, sulfur, nitrogen atoms, and the characteristic ring systems in the molecule.*

FDA Label Image

Tizanidine-2 (Tizanidine 2)

A line graph showing plasma Tizanidine concentration (ng/ml) over time (hours) after dosing for four different Tizanidine 4 mg formulations: tablets with food, tablets without food, capsules with food, and capsules without food. The graph compares absorption profiles from 0 to 24 hours post-dose.*

FDA Label Image

Tizanidine-3 (Tizanidine 3)

A line graph showing the improvement in Ashworth Score over time (0 to 6 hours post-dose) for three groups: 16 mg tizanidine, 8 mg tizanidine, and placebo. Improvement peaks around 2 hours post-dose for 16 mg and 8 mg tizanidine, then gradually declines. Placebo shows minimal improvement throughout.*

FDA Label Image

Tizanidine-4 (Tizanidine 4)

A line graph depicting improvement in Ashworth Score over time for two groups: tizanidine (mean dose 28.8 mg) and placebo. The x-axis marks study weeks 3, 7, and the endpoint, while the y-axis represents improvement scores, with tizanidine showing greater improvement than placebo throughout the study periods.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.